JP2010100624A5 - - Google Patents

Download PDF

Info

Publication number
JP2010100624A5
JP2010100624A5 JP2009259497A JP2009259497A JP2010100624A5 JP 2010100624 A5 JP2010100624 A5 JP 2010100624A5 JP 2009259497 A JP2009259497 A JP 2009259497A JP 2009259497 A JP2009259497 A JP 2009259497A JP 2010100624 A5 JP2010100624 A5 JP 2010100624A5
Authority
JP
Japan
Prior art keywords
angptl3
antibody
medicament
medicament according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009259497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010100624A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010100624A publication Critical patent/JP2010100624A/ja
Publication of JP2010100624A5 publication Critical patent/JP2010100624A5/ja
Pending legal-status Critical Current

Links

JP2009259497A 2001-11-16 2009-11-13 アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法 Pending JP2010100624A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33242901P 2001-11-16 2001-11-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003545797A Division JP5105696B2 (ja) 2001-11-16 2002-11-13 アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法

Publications (2)

Publication Number Publication Date
JP2010100624A JP2010100624A (ja) 2010-05-06
JP2010100624A5 true JP2010100624A5 (enExample) 2011-02-03

Family

ID=23298191

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003545797A Expired - Fee Related JP5105696B2 (ja) 2001-11-16 2002-11-13 アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法
JP2009259497A Pending JP2010100624A (ja) 2001-11-16 2009-11-13 アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003545797A Expired - Fee Related JP5105696B2 (ja) 2001-11-16 2002-11-13 アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法

Country Status (14)

Country Link
US (3) US7267819B2 (enExample)
EP (1) EP1451578B1 (enExample)
JP (2) JP5105696B2 (enExample)
KR (2) KR20100029861A (enExample)
CN (2) CN1615440A (enExample)
AU (1) AU2002348286B2 (enExample)
CA (1) CA2464542C (enExample)
ES (1) ES2429034T3 (enExample)
IL (2) IL161542A0 (enExample)
MX (1) MXPA04004609A (enExample)
NO (1) NO336021B1 (enExample)
NZ (1) NZ532852A (enExample)
WO (1) WO2003044172A2 (enExample)
ZA (1) ZA200403070B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2429034T3 (es) 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas
AU2004266043B2 (en) * 2003-08-21 2007-09-20 Duchesnay Inc. Micronutrient supplement
CA2574791A1 (en) * 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US7807645B2 (en) 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
WO2008073300A2 (en) * 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
US8354111B2 (en) 2008-04-14 2013-01-15 Hadasit Medical Research Services And Development Ltd. Stable cell binding chimeric peptides
CN101852805B (zh) * 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
CN111700901A (zh) 2010-01-08 2020-09-25 Ionis制药公司 血管生成素样3表达的调节
AU2015200969A1 (en) * 2010-01-08 2015-03-19 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
EP2517028B1 (en) * 2010-02-02 2017-12-13 Arizona Board Of Regents Controlled tunnel gap device for sequencing polymers
EP2668499A4 (en) * 2011-01-29 2015-05-27 Astute Medical Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
JP6249447B2 (ja) 2012-01-24 2017-12-20 インターケー・ペプチド・セラピューティクス・リミテッド 癌治療用ペプチド剤
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
CN104062432B (zh) * 2013-03-22 2016-01-20 中山大学 ang2在制备ECTC血管类型肝癌诊断试剂及治疗药物中的应用
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
HUE052243T2 (hu) 2013-12-24 2021-04-28 Ionis Pharmaceuticals Inc Az angiopoietin-szerû 3 expressziójának modulációja
MX382230B (es) 2014-05-01 2025-03-13 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
CN105021827B (zh) * 2015-07-17 2016-09-28 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
EP3370708A4 (en) 2015-11-06 2019-06-26 Ionis Pharmaceuticals, Inc. MODULATION OF APOLIPOPROTEIN (A) EXPRESSION
EP3411392B1 (en) * 2016-02-04 2021-12-29 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
MX2018010401A (es) 2016-03-03 2019-03-06 Regeneron Pharma Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3.
PE20201287A1 (es) * 2017-09-14 2020-11-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020099482A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
CN111122872B (zh) * 2019-11-20 2023-01-20 中山大学附属第一医院 血管生成素样蛋白7在心力衰竭预后评估中的应用
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
US20240141029A1 (en) * 2021-03-05 2024-05-02 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
CN114934021B (zh) * 2022-04-21 2023-08-08 复旦大学附属儿科医院 一种Angptl3敲除的鼠永生化足细胞系及其应用
CN120254294B (zh) * 2025-06-05 2025-09-09 南昌大学第一附属医院 Angptl3在乙肝相关慢加急性肝衰竭预后中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
EP0917878A4 (en) 1997-02-26 2004-05-19 Toray Industries REMEDIES FOR HEPATITIS
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
JP2002533058A (ja) * 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 97個のヒト分泌タンパク質
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
KR100553300B1 (ko) 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
ES2429034T3 (es) 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas

Similar Documents

Publication Publication Date Title
JP2005521643A5 (enExample)
CN107667115B (zh) 针对埃博拉病毒糖蛋白的人抗体
EP3094644B1 (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
CN114057869B (zh) 针对中东呼吸综合征-冠状病毒刺突蛋白的人抗体
JP2012504602A5 (enExample)
JP2017113019A5 (enExample)
Wagner et al. Engineering therapeutic antibodies to combat infectious diseases
JP2021521843A5 (enExample)
JP2012121878A5 (enExample)
JP2010526028A5 (enExample)
JP2010502207A5 (enExample)
JP2017537084A5 (enExample)
JP2017507652A5 (enExample)
CN108064240A (zh) 针对流感血凝素的人抗体
JP2009537143A5 (enExample)
JP2017500018A5 (enExample)
JP2009225799A5 (enExample)
JP2010524489A5 (enExample)
JP2017533694A5 (enExample)
CA2624935A1 (en) Anti-myostatin antibodies
JP2015503909A5 (enExample)
JP2010536384A5 (enExample)
CN107921285A (zh) 多价乙型肝炎病毒抗原结合分子及其应用
JP2011505867A5 (enExample)
JP2010526076A5 (enExample)